Clinical Trials Browser

Phase 2 × Completed × cc-486 × Clear all

NCT02494258 2026-04-02

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

Phase 2 Completed

5 enrolled 10 charts

Other hematologic neoplasm

Hematologic Diseases, Neoplasms, Hematologic Neoplasms

NCT02546986 2025-08-08

Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer

Phase 2 Completed

100 enrolled 27 charts

Carcinoma, Non-Small-Cell Lung

NCT02250326 2024-09-19

abound2L+

Phase 2 Completed

240 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT03493646 2024-05-28

Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486

Phase 2 Completed

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT01845805 2022-10-04

Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine)

Phase 2 Completed

49 enrolled 10 charts

Gastrointestinal

Pancreatic Neoplasms

NCT02811497 2021-04-01

METADUR

Phase 2 Completed

BreastGastrointestinalGynecologic

Microsatellite Stable Colorectal Carcinoma

NCT02269943 2018-12-12

Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma

Phase 2 Completed

36 enrolled 24 charts

Nasopharyngeal Carcinoma, Head and Neck Neoplasms, Nasopharyngeal Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence, Epstein-Barr Virus Infections